ARTICLE | Product Development
Spotlight on early-stage solid tumor trials with emerging innate immune targets: ALPK1 and ENPP1
By Emily Arner, BioCentury Staff, and Karen Tkach Tuzman, Director of Biopharma Intelligence
April 25, 2024 10:23 PM UTC
First-in-human compounds at this year’s AACR meeting included two innate immune activators whose targets are the focus of a cluster of early programs in the clinic, providing another signal that the compound class is earning a second chance in cancer.
Enthusiasm for cancer therapies that simulate STING, and other innate immune regulators such as toll-like receptors (TLRs), had waned after systemic delivery of first-generation compounds proved too toxic. The innate immune agonist class is now seeing a resurgence via more targeted delivery as antibody-drug conjugate (ADC) payloads…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652178/innate-immune-activators-among-first-in-human-debuts-at-aacr